Nurix Therapeutics, Inc. (NRIX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Nurix Therapeutics reported revenue of $84.0M, up 54.0% from $54.5M the year before. Net income was -$264.5M (a -314.9% net margin), or -$3.05 per diluted share. Operating margin was -340.2%. Operating activities generated -$249.5M of cash, leaving -$263.5M of free cash flow. At fiscal year end, Nurix Therapeutics held $688.1M in total assets against $149.4M in total liabilities, including $247.0M of cash and equivalents.
Open the full interactive Nurix Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Nurix Therapeutics Key Stats
| Share Price | $22.13 |
|---|---|
| Market Cap | $2.57B |
| Revenue YoY Growth | +53.9% |
| 52-Week Range | $9.18 – $27.79 |
| Shares Outstanding | 111.6 million (basic, 2026 Q3) |
Nurix Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $17.8M | $29.8M | $38.6M | $77.0M | $54.5M | $84.0M |
| Operating Income | -$65.0M | -$117.9M | -$183.9M | -$155.1M | -$213.0M | -$285.7M |
| Pre-Tax Income | -$63.8M | -$117.1M | -$180.4M | -$143.9M | -$193.3M | -$263.7M |
| Income Tax | -$20.5M | $131,000 | $0 | — | $270,000 | $760,000 |
| Net Income | -$43.2M | -$117.2M | -$180.4M | -$143.9M | -$193.6M | -$264.5M |
| Diluted EPS | -$2.76 | -$2.73 | -$3.71 | -$2.65 | -$2.88 | -$3.05 |
Nurix Therapeutics Quarterly Results
| 2025 Q4 | 2026 Q1 | 2026 Q2 | 2026 Q3 | |
|---|---|---|---|---|
| Revenue | $13.6M | $6.3M | $9.0M | $673.1M |
| Net Income | -$78.2M | -$87.2M | -$89.5M | $549.8M |
| Diluted EPS | -$0.90 | -$0.79 | -$0.81 | $4.73 |
Nurix Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $119.4M | $80.5M | $64.5M | $54.6M | $110.0M | $247.0M |
| Current Assets | $298.4M | $311.1M | $318.4M | $295.5M | $619.4M | $606.8M |
| Total Assets | $396.3M | $476.8M | $416.8M | $355.6M | $669.3M | $688.1M |
| Current Liabilities | $44.5M | $66.3M | $70.7M | $87.0M | $95.9M | $86.5M |
| Total Liabilities | $106.1M | $134.5M | $113.1M | $155.1M | $142.3M | $149.4M |
| Shareholders' Equity | $290.3M | $342.3M | $303.7M | $200.5M | $527.0M | $538.7M |
Nurix Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$80,000 | -$84.4M | -$159.8M | -$81.4M | -$172.6M | -$249.5M |
| Cash From Investing | -$254.4M | -$108.3M | $27.2M | $68.3M | -$257.7M | $147.9M |
| Cash From Financing | $339.0M | $153.9M | $117.2M | $3.2M | $485.7M | $238.6M |
| Free Cash Flow | -$4.6M | -$90.1M | -$172.1M | -$89.8M | -$181.9M | -$263.5M |
Figures from Nurix Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Nurix Therapeutics financials page for every line item.
Nurix Therapeutics Company Profile
| Ticker | NRIX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Brisbane, California |
| Incorporated in | Delaware |
| Fiscal Year End | November 30 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001549595 |
Frequently Asked Questions
What was Nurix Therapeutics' revenue in fiscal 2025?
Nurix Therapeutics (NRIX) reported revenue of $84.0M for fiscal 2025.
What is Nurix Therapeutics' annual revenue history?
Nurix Therapeutics' annual revenue by fiscal year: 2020: $17.8M; 2021: $29.8M; 2022: $38.6M; 2023: $77.0M; 2024: $54.5M; 2025: $84.0M.
What was Nurix Therapeutics' net income in fiscal 2025?
Nurix Therapeutics reported net income of -$264.5M for fiscal 2025.
What was Nurix Therapeutics' earnings per share (EPS) in fiscal 2025?
Nurix Therapeutics' diluted EPS was -$3.05 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Nurix Therapeutics generate in fiscal 2025?
Nurix Therapeutics generated -$263.5M of free cash flow in fiscal 2025.
What was Nurix Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q3), Nurix Therapeutics reported revenue of $673.1M.
How many shares of Nurix Therapeutics are outstanding?
Nurix Therapeutics reported a weighted average of 111.6 million basic shares outstanding in 2026 Q3.
What is Nurix Therapeutics' market cap?
Based on its latest closing price, Nurix Therapeutics (NRIX) has a market capitalization of about $2.57B.
When does Nurix Therapeutics' fiscal year end?
Nurix Therapeutics' fiscal year end, as registered with the SEC, is November 30.
Where is Nurix Therapeutics headquartered?
Nurix Therapeutics lists its business address in Brisbane, California in its SEC filings.